PMID- 21335133
OWN - NLM
STAT- MEDLINE
DCOM- 20110408
LR  - 20181201
IS  - 1097-685X (Electronic)
IS  - 0022-5223 (Linking)
VI  - 141
IP  - 3
DP  - 2011 Mar
TI  - Methylation of the promoter of human leukocyte antigen class I in human 
      esophageal squamous cell carcinoma and its histopathological characteristics.
PG  - 808-14
LID - 10.1016/j.jtcvs.2010.04.031 [doi]
AB  - OBJECTIVE: The downregulation of human leukocyte antigen class I (HLA-I) has been 
      proposed to contribute to the immune evasion of cancer cells in some cancers. 
      Meanwhile, transcriptional silencing by means of promoter methylation is now 
      believed to be an important mechanism of carcinogenesis. The aim of this study 
      was (1) to examine the expression of HLA-I antigen and the antigen-processing 
      machinery components in patients with esophageal squamous cell carcinoma lesions 
      and (2) to detect the methylation pattern of the HLA-I gene in patients with 
      esophageal squamous cell carcinoma and assess its association with 
      histopathological characteristics. METHODS: A total of 87 formalin-fixed and 
      paraffin-embedded esophageal squamous cell carcinoma lesions were collected. 
      HLA-I and antigen-processing machinery component expression was investigated by 
      means of immunohistochemistry with anti-HLA-I monoclonal antibody, and 
      methylation changes in the promoter region of HLA-1 genes were determined by 
      using methylation-specific polymerase chain reaction. RESULTS: HLA-I, transporter 
      associated with antigen processing 1, and low molecular weight protein were lost 
      or downregulated in 67%, 29.8%, and 47.0% of the esophageal squamous cell 
      carcinoma lesions, respectively. The positive rates of gene promoter 
      hypermethylation of HLA-I was 70.1% (61/87) in tumor tissues compared with 3.6% 
      in normal tissue (P < .01). Also, the higher methylation rates and the HLA-I 
      expression were significantly associated with tumor grade, including lymph node 
      metastasis (P < .05). CONCLUSIONS: HLA-I promoter hypermethylation was associated 
      with loss of HLA-I antigen, which frequently occurred in primary tumors, 
      especially in metastatic lymph node lesions, and was associated with patients' 
      prognoses.
CI  - Copyright (c) 2011. Published by Mosby, Inc.
FAU - Qifeng, Sun
AU  - Qifeng S
AD  - Thoracic Surgery, Second Hospital of Shandong University, Jinan, China.
FAU - Bo, Cong
AU  - Bo C
FAU - Xingtao, Jiang
AU  - Xingtao J
FAU - Chuanliang, Peng
AU  - Chuanliang P
FAU - Xiaogang, Zhao
AU  - Xiaogang Z
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 2)
RN  - 0 (ATP-Binding Cassette Transporters)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (TAP1 protein, human)
RN  - 0 (transporter associated with antigen processing (TAP))
RN  - 144416-78-4 (LMP-2 protein)
RN  - EC 3.4.22.- (Cysteine Endopeptidases)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 2
MH  - ATP-Binding Cassette Transporters/analysis
MH  - Carcinoma, Squamous Cell/*genetics/immunology/mortality/pathology
MH  - Chi-Square Distribution
MH  - China
MH  - CpG Islands
MH  - Cysteine Endopeptidases/analysis
MH  - *DNA Methylation
MH  - Down-Regulation
MH  - Esophageal Neoplasms/*genetics/immunology/mortality/pathology
MH  - Female
MH  - Genotype
MH  - Histocompatibility Antigens Class I/analysis/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - Lymphatic Metastasis
MH  - Major Histocompatibility Complex
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Phenotype
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - *Promoter Regions, Genetic
MH  - Proportional Hazards Models
MH  - Survival Analysis
MH  - Time Factors
EDAT- 2011/02/22 06:00
MHDA- 2011/04/09 06:00
CRDT- 2011/02/22 06:00
PHST- 2010/01/31 00:00 [received]
PHST- 2010/04/26 00:00 [revised]
PHST- 2010/04/30 00:00 [accepted]
PHST- 2011/02/22 06:00 [entrez]
PHST- 2011/02/22 06:00 [pubmed]
PHST- 2011/04/09 06:00 [medline]
AID - S0022-5223(10)00437-X [pii]
AID - 10.1016/j.jtcvs.2010.04.031 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 2011 Mar;141(3):808-14. doi: 
      10.1016/j.jtcvs.2010.04.031.